Literature DB >> 29021378

Outcomes of a Specialized Interdisciplinary Approach for Patients with Cancer with Aberrant Opioid-Related Behavior.

Joseph Arthur1, Tonya Edwards2, Suresh Reddy2, Kristy Nguyen2, David Hui2, Sriram Yennu2, Minjeong Park3, Diane Liu3, Eduardo Bruera2.   

Abstract

BACKGROUND: Data on the development and outcomes of effective interventions to address aberrant opioid-related behavior (AB) in patients with cancer are lacking. Our outpatient supportive care clinic developed and implemented a specialized interdisciplinary team approach to manage patients with AB. The purpose of this study was to report clinical outcomes of this novel intervention.
MATERIALS AND METHODS: The medical records of 30 consecutive patients with evidence of AB who received the intervention and a random control group of 70 patients without evidence of AB between January 1, 2015, and August 31, 2016, were reviewed.
RESULTS: At baseline, pain intensity (p = .002) and opioid dose (p = .001) were significantly higher among patients with AB. During the course of the study, the median number of ABs per month significantly decreased from three preintervention to 0.4 postintervention (p < .0001). The median morphine equivalent daily dose decreased from 165 mg/day at the first intervention visit to 112 mg/day at the last follow-up (p = .018), although pain intensity did not significantly change (p = .984). "Request for opioid medication refills in the clinic earlier than the expected time" was the AB with the highest frequency prior to the intervention and the greatest improvement during the study period. Younger age (p < .0001) and higher Edmonton Symptom Assessment System anxiety score (p = .005) were independent predictors of the presence of AB.
CONCLUSION: The intervention was associated with a reduction in the frequency of AB and opioid utilization among patients with cancer receiving chronic opioid therapy. More research is needed to further characterize the clinical effectiveness of this intervention. IMPLICATIONS FOR PRACTICE: There are currently no well-defined and evidence-based strategies to manage cancer patients on chronic opioid therapy who demonstrate aberrant opioid-related behavior. The findings of this study offer a promising starting point for the creation of a standardized strategy for clinicians and provides valuable information to guide their practice regarding these patients. The study results will also help clinicians to better understand the types and frequencies of the most common aberrant behaviors observed among patients with cancer who are receiving chronic opioid therapy. This will enhance the process of timely patient identification, management, or referral to the appropriate specialist teams. © AlphaMed Press 2017.

Entities:  

Keywords:  Aberrant behavior; Cancer; Interdisciplinary approach; Intervention; Opioids; Team

Mesh:

Substances:

Year:  2017        PMID: 29021378      PMCID: PMC5813743          DOI: 10.1634/theoncologist.2017-0248

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  46 in total

1.  Screening for substance abuse risk in cancer patients using the Opioid Risk Tool and urine drug screen.

Authors:  Joshua S Barclay; Justine E Owens; Leslie J Blackhall
Journal:  Support Care Cancer       Date:  2014-02-23       Impact factor: 3.603

2.  A comparison of common screening methods for predicting aberrant drug-related behavior among patients receiving opioids for chronic pain management.

Authors:  Todd M Moore; Ted Jones; Joe H Browder; Susan Daffron; Steven D Passik
Journal:  Pain Med       Date:  2009-11       Impact factor: 3.750

Review 3.  Assessment and management of chemical coping in patients with cancer.

Authors:  Egidio Del Fabbro
Journal:  J Clin Oncol       Date:  2014-05-05       Impact factor: 44.544

4.  Aberrant Opioid Use and Urine Drug Testing in Outpatient Palliative Care.

Authors:  Joseph A Arthur; Ali Haider; Tonya Edwards; Jessica Waletich-Flemming; Suresh Reddy; Eduardo Bruera; David Hui
Journal:  J Palliat Med       Date:  2016-05-12       Impact factor: 2.947

5.  Do Palliative Care Clinics Screen for Substance Abuse and Diversion? Results of a National Survey.

Authors:  Paul D Tan; Joshua S Barclay; Leslie J Blackhall
Journal:  J Palliat Med       Date:  2015-06-05       Impact factor: 2.947

6.  Risk stratification of opioid misuse among patients with cancer pain using the SOAPP-SF.

Authors:  Dhanalakshmi Koyyalagunta; Eduardo Bruera; Carrie Aigner; Harun Nusrat; Larry Driver; Diane Novy
Journal:  Pain Med       Date:  2013-04-30       Impact factor: 3.750

7.  Frequency and predictors of patient deviation from prescribed opioids and barriers to opioid pain management in patients with advanced cancer.

Authors:  Linh M T Nguyen; Wadih Rhondali; Maxine De la Cruz; David Hui; Lynn Palmer; Duck-Hee Kang; Henrique A Parsons; Eduardo Bruera
Journal:  J Pain Symptom Manage       Date:  2012-08-30       Impact factor: 3.612

8.  Predictors of resolution of aberrant drug behavior in chronic pain patients treated in a structured opioid risk management program.

Authors:  Salimah H Meghani; Nancy L Wiedemer; William C Becker; Ed J Gracely; Rollin M Gallagher
Journal:  Pain Med       Date:  2009-06-11       Impact factor: 3.750

9.  Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group.

Authors:  G Apolone; O Corli; A Caraceni; E Negri; S Deandrea; M Montanari; M T Greco
Journal:  Br J Cancer       Date:  2009-04-28       Impact factor: 7.640

10.  Use of Palliative Care Services in a Tertiary Cancer Center.

Authors:  Shalini Dalal; Sebastian Bruera; David Hui; Sriram Yennu; Rony Dev; Janet Williams; Charles Masoni; Ijeoma Ihenacho; Emmanuel Obasi; Eduardo Bruera
Journal:  Oncologist       Date:  2015-11-27
View more
  10 in total

Review 1.  Best Practices in the Management of Nonmedical Opioid Use in Patients with Cancer-Related Pain.

Authors:  Esad Ulker; Egidio Del Fabbro
Journal:  Oncologist       Date:  2019-12-24

Review 2.  Opioid Prescribing in an Opioid Crisis: What Basic Skills Should an Oncologist Have Regarding Opioid Therapy?

Authors:  Joseph Arthur; Akhila Reddy
Journal:  Curr Treat Options Oncol       Date:  2019-04-01

Review 3.  Improving patient and caregiver outcomes in oncology: Team-based, timely, and targeted palliative care.

Authors:  David Hui; Breffni L Hannon; Camilla Zimmermann; Eduardo Bruera
Journal:  CA Cancer J Clin       Date:  2018-09-13       Impact factor: 508.702

Review 4.  Stringent Control of Opioids: Sound Public Health Measures, but a Step Too Far in Palliative Care?

Authors:  Ross Pinkerton; Geoffrey Mitchell; Janet Hardy
Journal:  Curr Oncol Rep       Date:  2020-03-13       Impact factor: 5.075

Review 5.  Pancreatic cancer-A disease in need: Optimizing and integrating supportive care.

Authors:  Gordon T Moffat; Andrew S Epstein; Eileen M O'Reilly
Journal:  Cancer       Date:  2019-08-05       Impact factor: 6.860

6.  Management of Pain in the United States-A Brief History and Implications for the Opioid Epidemic.

Authors:  Stephen A Bernard; Paul R Chelminski; Timothy J Ives; Shabbar I Ranapurwala
Journal:  Health Serv Insights       Date:  2018-12-26

Review 7.  Navigating Challenging Conversations About Nonmedical Opioid Use in the Context of Oncology.

Authors:  Zachary Sager; Julie Childers
Journal:  Oncologist       Date:  2019-05-31

8.  Factors Influencing Pain Expression in Patients with Cancer: An Expert Opinion.

Authors:  Sebastiano Mercadante; Flaminia Coluzzi
Journal:  Pain Ther       Date:  2021-05-20

Review 9.  Depression and Long-Term Prescription Opioid Use and Opioid Use Disorder: Implications for Pain Management in Cancer.

Authors:  Nicole Bates; Jennifer K Bello; Nosayaba Osazuwa-Peters; Mark D Sullivan; Jeffrey F Scherrer
Journal:  Curr Treat Options Oncol       Date:  2022-03-07

Review 10.  Telemedicine and Its Past, Present, and Future Roles in Providing Palliative Care to Advanced Cancer Patients.

Authors:  Michael Tang; Akhila Reddy
Journal:  Cancers (Basel)       Date:  2022-04-08       Impact factor: 6.575

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.